<DOC>
	<DOCNO>NCT03058692</DOCNO>
	<brief_summary>This Phase II randomize , double-blind , placebo-controlled trial 240 male non-pregnant female , 18 45 year old , inclusive , good health meet eligibility criterion . This clinical trial design assess safety , reactogenicity , immunogenicity two priming dos M-001 follow boost two dos MF59-adjuvanted non-adjuvanted monovalent influenza A/H7N9 IIV . The monovalent influenza A/H7N9 IIV derive HA influenza A/Shanghai/2/2013 ( H7N9 ) virus . Primary objective : To assess safety reactogenicity M-001 vaccine follow receipt two dos ; To assess safety reactogenicity monovalent inactivate influenza A/H7N9 vaccine ( A/H7N9 IIV ; two dos ) administer without MF59 adjuvant follow immunization two dose M-001 vaccine placebo , assess serum hemagglutination inhibition ( HAI ) antibody responses A/H7N9 IIV virus receipt first second dose MF59 adjuvanted non-adjuvanted A/H7N9 IIV administer adult follow receipt placebo two dos M-001 vaccine .</brief_summary>
	<brief_title>Two Doses Multimeric-001 ( M-001 ) Followed Two Doses Influenza A/H7N9 Vaccine</brief_title>
	<detailed_description>This Phase II randomize , double-blind , placebo-controlled trial 240 male non-pregnant female , 18 45 year old , inclusive , good health meet eligibility criterion . This clinical trial design assess safety , reactogenicity , immunogenicity two priming dos M-001 follow boost two dos MF59-adjuvanted non-adjuvanted monovalent influenza A/H7N9 IIV . The monovalent influenza A/H7N9 IIV derive HA influenza A/Shanghai/2/2013 ( H7N9 ) virus . The duration trial subject approximately 15 month . Primary objective : To assess safety reactogenicity M-001 vaccine follow receipt two dos ; To assess safety reactogenicity monovalent inactivate influenza A/H7N9 vaccine ( A/H7N9 IIV ; two dos ) administer without MF59 adjuvant follow immunization two dose M-001 vaccine placebo , assess serum hemagglutination inhibition ( HAI ) antibody responses A/H7N9 IIV virus receipt first second dose MF59 adjuvanted non-adjuvanted A/H7N9 IIV administer adult follow receipt placebo two dos M-001 vaccine . Secondary Objectives : To assess unsolicited AEs follow receipt two dose M-001 placebo follow receipt two dos MF59 adjuvanted non-adjuvanted A/H7N9 IIV ; To assess medically-attended adverse event ( MAAEs ) include new-onset chronic medical condition ( NOCMCs ) potentially immune-mediated medical condition ( PIMMCs ) follow receipt two dose M-001 placebo follow receipt two dos MF59 adjuvanted non-adjuvanted A/H7N9 IIV , ass serum neutralizing ( Neut ) antibody responses influenza A/H7N9 vaccine virus receipt first second dose MF59 adjuvanted non-adjuvanted A/H7N9 IIV administer adult follow receipt placebo two dos M-001 vaccine .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>1 . Provide write informed consent prior initiation study procedure . 2 . Are able understand comply plan study procedure available study visit . 3 . Are male nonpregnant female , 18 45 year old , inclusive . 4 . Are good health , determine vital sign % , medical history , target physical examination ensure exist medical diagnosis condition ( except exclusionary ) stable . Vital sign include oral temperature , pulse , blood pressure . Stable chronic medical condition change prescription medication , dose , frequency medication last 3 month ( define 90 day ) health outcome specific disease consider within acceptable limit last 6 month ( define 180 day ) . Any change due change health care provider , insurance company etc. , do financial reason , long class medication , consider violation inclusion criterion . Any change prescription medication due improvement disease outcome , determine site principal investigator appropriate subinvestigator , consider violation inclusion criterion . Subjects may chronic need ( prn ) medication , opinion site principal investigator appropriate subinvestigator , pose additional risk subject safety assessment reactogenicity immunogenicity . Note : Topical , nasal , inhaled medication ( exception steroid outline Subject Exclusion Criteria ( see Section 5.2 ) ) , vitamin , contraceptive permit . 5 . Oral temperature less 100.0°F . 6 . Pulse 50 115 bpm , inclusive . 7 . Systolic blood pressure 85 150 mm Hg , inclusive . 8 . Diastolic blood pressure 55 95 mmHg , inclusive . 9 . Women childbearing potential‡ must use acceptable method contraception§ 30 day prior vaccination 60 day last study vaccination . Not sterilize via tubal ligation , bilateral oophorectomy , hysterectomy , successful Essure® placement ( permanent , nonsurgical , nonhormonal sterilization ) document radiological confirmation test least 90 day procedure , still menstruate &lt; 1 year last menses menopausal ) . Includes , limit , nonmale sexual relationship , abstinence sexual intercourse male partner , monogamous relationship vasectomize partner , male condom use applied spermicide , intrauterine device , NuvaRing® , license hormonal method implant , injectables , contraceptive patch oral contraceptive ( `` pill '' ) . Method contraception capture appropriate data collection form . 10 . Female subject childbearing potential must negative urine serum pregnancy test within 24 hour prior study vaccination . 1 . Have acute illness1 , determine site PI appropriate subinvestigator , within 72 hour prior study vaccination . An acute illness nearly resolve minor residual symptom remain allowable , opinion site PI appropriate subinvestigator , residual symptom interfere ability ass safety parameter require protocol . 2 . Have medical disease condition , opinion site PI appropriate subinvestigator , contraindication study participation2 . Including acute chronic medical disease condition , define persist least 90 day , would place subject unacceptable risk injury , render subject unable meet requirement protocol , may interfere evaluation response subject 's successful completion study . 3 . Have immunosuppression result underlie illness treatment , use anticancer chemotherapy radiation therapy ( cytotoxic ) within 3 year prior study vaccination . 4 . Have know active neoplastic disease history hematologic malignancy . Nonmelanoma skin cancer active permit . 5 . Have know HIV , hepatitis B , hepatitis C infection . 6 . Have know hypersensitivity allergy egg , egg chicken protein , component study vaccine . 7 . Have history severe reaction follow previous immunization license unlicensed influenza vaccine . 8 . Have history GuillainBarré Syndrome . 9 . Have history alcohol drug abuse within 5 year prior study vaccination . 10 . Have diagnosis , current past , schizophrenia , bipolar disease , psychiatric diagnosis may interfere subject compliance safety evaluation . 11 . Have hospitalize psychiatric illness , history suicide attempt , confinement danger self others within 10 year prior study vaccination . 12 . Have take oral parenteral ( include intraarticular ) corticosteroid dose within 30 day prior study vaccination . 13 . Have take highdose3 dose inhaled corticosteroid within 30 day prior study vaccination . Highdose define &gt; 840 mcg/day beclomethasone dipropionate CFC equivalent . Topical nasal steroid permissible . 14 . Received licensed live vaccine within 30 day prior first study vaccination . 15 . Received licensed inactivated vaccine within 14 day prior first study vaccination . 16 . Received influenza vaccine ( inactivated live ) within 30 day prior first study vaccination . 17 . Plans receive license vaccine time first study vaccination followup visit approximately 21 day last study vaccination . 18 . Received immunoglobulin blood product ( exception Rho D immunoglobulin ) within 90 day prior study vaccination . 19 . Received experimental agent5 within 30 day prior first study vaccination , expect receive experimental agent6 15month trialreporting period . Including vaccine , drug , biologic , device , blood product , medication . Other participation study . 20 . Are participate plan participate another clinical trial interventional agent7 receive 15month trialreporting period . include agent ( license unlicensed vaccine , drug , biologic , device , blood product , medication ) 9month study period . 21 . Prior participation clinical trial influenza A/H7 vaccine history A/H7 actual potential exposure infection prior first study vaccination . assign group receive influenza A/H7 vaccine ( apply document placebo recipient ) 22 . Plan travel outside U.S. ( continental U.S. , Hawaii Alaska ) time first study vaccination 21 day last study vaccination . 23 . Female subject breastfeed plan breastfeed give time first study vaccination 30 day last study vaccination . 24 . Blood donation plan blood donation within 30 day prior study vaccination 30 day last blood drawn study . 25 . Have sign symptom could confound confuse assessment study vaccine reactogenicity . The study vaccination postponed/deferred sign symptom resolve within acceptable protocolspecified window visit . 26 . Have history convulsion encephalomyelitis within 90 day prior study vaccination . 27 . Have history potentially immunemediated medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2, 2017</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Influenza A/H7N9 Vaccine</keyword>
	<keyword>M-001 vaccine</keyword>
	<keyword>MF59 Adjuvant</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>Safety</keyword>
</DOC>